#	Pagina
attuale pagina	/open-h2020/projects/207227/index.html
-1	/open-h2020/per-topic/vesiculation/list/index.html
-2	/open-h2020/per-topic/leftpad/list/index.html

Opendata, web and dolomites

EURE-CART SIGNED

EURopean Endeavour for Chimeric Antigen Receptor Therapies

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

EURE-CART project word cloud

Explore the words cloud of the EURE-CART project. It provides you a very rough idea of what is the project "EURE-CART" about.

excellences regulatory uniquely expensive instalment diseases adoptive academia centralisation cart national therapy unprecedented successful though track enormously car alliance industry anti proposes involvement countries incurable causing establishment bodies approval meet conducting billions extend receptor molmed secondary spa modified oncology pioneers smes forefront cell accelerating gene eradicate tackled create chimeric reactive respective cells centres personalised frequent death eure therapeutic ultimate causes chronic antigen tumour clinical first defeating experts applicability record never jobs endowed enterprise secure demonstrated trial unparalleled representing cancer stage struggles immunotherapy academic man therapies leaders innovative tumours genetically eur constrains

Project "EURE-CART" data sheet

The following table provides information about the project.

Coordinator	MOLECULAR MEDICINE SPA Organization address address: VIA OLGETTINA 58 city: MILANO postcode: 20132 website: www.molmed.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Project website	https://www.eure-cart.eu/
Total cost	5˙903˙146 €
EC max contribution	5˙903˙146 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2016-RTD
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2020-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	MOLECULAR MEDICINE SPA MOLECULAR MEDICINE SPA Organization address address: VIA OLGETTINA 58 city: MILANO postcode: 20132 website: www.molmed.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	coordinator	1˙994˙575.00
2	OSPEDALE SAN RAFFAELE SRL OSPEDALE SAN RAFFAELE SRL Organization address address: VIA OLGETTINA 60 city: MILANO postcode: 20132 website: www.hsr.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	participant	1˙112˙500.00
3	UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT Organization address address: JOSEF-SCHNEIDER-STRASSE 2 city: WURZBURG postcode: 97080 website: www.uk-wuerzburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (WURZBURG)	participant	856˙076.00
4	OSPEDALE PEDIATRICO BAMBINO GESU OSPEDALE PEDIATRICO BAMBINO GESU Organization address address: PIAZZA SANT ONOFRIO 4 city: ROMA postcode: 165 website: www.ospedalebambinogesu.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	participant	492˙431.00
5	ACROMION GMBH ACROMION GMBH Organization address address: EUROPAALLEE 27-29 city: FRECHEN postcode: 50226 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (FRECHEN)	participant	398˙000.00
6	ARTTIC ARTTIC Organization address address: RUE DU DESSOUS DES BERGES 58A city: PARIS postcode: 75013 website: www.arttic.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	375˙000.00
7	FUNDACIO PRIVADA INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU FUNDACIO PRIVADA INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU Organization address address: CALLE SANT ANTONI M CLARET 167 city: BARCELONA postcode: 8025 website: www.santpau.cat contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	225˙011.00
8	ISTITUTO SUPERIORE DI SANITA ISTITUTO SUPERIORE DI SANITA Organization address address: Viale Regina Elena 299 city: ROMA postcode: 161 website: http://www.iss.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	participant	225˙000.00
9	FAKULTNI NEMOCNICE OSTRAVA FAKULTNI NEMOCNICE OSTRAVA Organization address address: 17 LISTOPADU 1790 city: OSTRAVA PORUBA postcode: 708 52 website: www.fno.cz contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CZ (OSTRAVA PORUBA)	participant	224˙552.00

Map

Project objective

Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing secondary chronic diseases. This approach is already at an advanced stage of development in the US, but struggles in the EU, due to a number of constrains that will be specifically tackled by this Project. The ultimate goal of EURE-CART is to bring EU at the forefront CAR T-cell immunotherapy. In this Project, we will extend the applicability of CAR T-cell immunotherapy to incurable tumours that have never been tackled with this approach. The EURE-CART Consortium is composed of 6 academic centres, 2 SMEs and 1 large enterprise from 6 EU countries, clearly representing excellences in their respective fields. EURE-CART will bring together clinical experts in oncology, and pioneers and leaders in the field of cell and gene therapy for conducting a first-in-man Phase I/II clinical trial. To be successful, EURE-CART proposes the early involvement of National regulatory authorities for accelerating the approval of CAR T-cell immunotherapy, as well as the centralisation of its production by the Molmed Spa. Molmed Spa is uniquely endowed in the EU with the know-how and experience necessary to meet this ambitious objective, as demonstrated by its unparalleled track record. The main expected impact of EURE-CART is the establishment of CAR T-cell therapy as the ultimate personalised therapy, capable of defeating chronic diseases, and to create secure new jobs in the EU through the instalment of an unprecedented alliance between academia, industry and regulatory bodies.

Deliverables

List of deliverables.
Preparation of a project logo and flyer	Websites, patent fillings, videos etc.	2019-05-31 16:44:17
Individualised press releases	Websites, patent fillings, videos etc.	2019-05-31 17:41:12
Signing-up of dedicated Twitter and LinkedIn accounts	Websites, patent fillings, videos etc.	2019-05-31 17:41:08
Launch of dedicated website	Websites, patent fillings, videos etc.	2019-05-31 16:44:21

Take a look to the deliverables list in detail: detailed list of EURE-CART deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	\"\"\"F. Moretti, F. Capone, C. Traversari, M.C. Galli\" Il Progetto europeo EURE-CART: l\'ISS tra i partner del nuovo approccio terapeutico e personalizzato per sconfiggere le malattie neoplastiche published pages: 3-5, ISSN: 1827-6296, DOI:	Notiziario Istituto Superiore SanitÃ 31(11)	2020-03-05
2018	Franco Locatelli, Concetta Quintarelli The EURE-CART project as a prototype model for CAR T-cell immunotherapy in Europe published pages: 216-219, ISSN: 0014-2980, DOI: 10.1002/eji.201870029	European Journal of Immunology 48/2	2019-06-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EURE-CART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EURE-CART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination